Elanco Animal Health beats Q2 revenue estimates, raises FY  guidance

Elanco Animal Health Incorporated

05/08/2026 11:36

Overview
US animal health firm's Q2 revenue rose 10%, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year revenue and adjusted EPS guidance

Outlook
Elanco raises 2026 revenue guidance to $5.09 bln-$5.14 bln from $5.01 bln-$5.085 bln
Company lifts 2026 adjusted EPS forecast to $1.10-$1.16 from $1.03-$1.09
Elanco expects Q3 revenue of $1.195 bln-$1.22 bln and adjusted EPS of $0.19-$0.22

Result Drivers
NEW PRODUCTS - Zenrelia and Credelio Quattro were the largest contributors to global growth, per company statement
PET HEALTH DEMAND - U.S. Pet Health segment revenue rose, led by strong demand for innovative products
FAVORABLE MIX AND PRICING - Gross margin expansion was driven by favorable mix from U.S. Pet Health and increased pricing, partially offset by higher inventory costs

Company press release: ID:nPn2QB7xba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.37 bln
$1.31 bln (12 Analysts)
Q2 Adjusted EPS
Beat
$0.34
$0.27 (14 Analysts)
Q2 EPS
 
$0.11
 
Q2 Adjusted Net Income
Beat
$174 mln
$138.72 mln (12 Analysts)
Q2 Net Income
 
$54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Elanco Animal Health Incorporated is $30.00, about 17.2% above its August 4 closing price of $25.60
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
Aug 4 - MGAs fuel rapid, profitable growth in US pet insurance: AM Best
Aug 5 - Singapore's Asia Vets Holdings half-year revenue rises, pretax loss narrows
Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)